KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $103.1 million.

  • Jazz Pharmaceuticals' Other Non-Current Assets rose 3700.2% to $103.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.1 million, marking a year-over-year increase of 3700.2%. This contributed to the annual value of $114.5 million for FY2024, which is 6969.35% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Other Non-Current Assets stood at $103.1 million, which was up 3700.2% from $121.3 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Other Non-Current Assets peaked at $121.3 million during Q2 2025, and registered a low of $30.4 million during Q1 2021.
  • In the last 5 years, Jazz Pharmaceuticals' Other Non-Current Assets had a median value of $67.5 million in 2023 and averaged $69.8 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Other Non-Current Assets tumbled by 3557.01% in 2021, and later skyrocketed by 19945.64% in 2022.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Other Non-Current Assets stood at $40.8 million in 2021, then skyrocketed by 35.1% to $55.1 million in 2022, then increased by 22.35% to $67.5 million in 2023, then surged by 69.69% to $114.5 million in 2024, then dropped by 9.97% to $103.1 million in 2025.
  • Its Other Non-Current Assets was $103.1 million in Q3 2025, compared to $121.3 million in Q2 2025 and $116.5 million in Q1 2025.